Look-alike and sound-alike medicines: risks and ‘solutions’
MetadataShow full item record
The final publication is available at: http://www.springerlink.com
‘Look-alike, sound-alike’ medicines are associated with dispensing errors. This commentary aims to fuel discussion surrounding how drug name nomenclature and similar packaging between medicines can lead to selection errors, the need for enhanced approval systems for medicine names and packaging, and best practice ‘solutions’. The literature reveals a number of environmental risks and human factors that can contribute to such errors. To contextualise these risks, we interviewed 13 quality and safety experts, psycholinguists, and hospital and community pharmacy practitioners in Australia, and commissioned a medical software industry expert to conceptualise electronic initiatives. Environmental factors contributing to such errors, identified through both the literature and interviews, include distractions during dispensing; workflow controls should minimise the ‘human factors’ element of errors. Technological solutions with some support, and yet recognised limitations, include font variations, automated alerts, barcode scanning and real-time reporting programmed into dispensing software; further development of these initiatives is recommended.
Showing items related by title, author, creator and subject.
McKnight, David (2011)Background: Medication Safety has become a major health issue in Australia and internationally. Medication use is a part of most people lives with around seven in ten Australians and nine in ten older Australians having ...
Emmerton, Lynne ; Curtain, C.; Swaminathan, G.; Dowling, H. (2020)Background: ‘Look-alike, sound-alike’ (LASA) medicines may be confused by prescribers, pharmacists, nurses and patients, with serious consequences for patient safety. The current research aimed to develop and trial software ...
Shepherd, A.; Perrella, B.; Hattingh, H. Laetitia (2014)Background: Opioid substitution therapy (OST) programs involve the dispensing of OST medicines to patients to address their dependence on heroin and/or other opioid substances. OST medicines are subsidised by the Australian ...